There are currently 578 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Norton Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Effects of RISE on Eating Pathology
NCT05837312
Recruiting
Interoception is the process of perceiving one's bodily sensations. Interoception is critical for survival and maintaining homeostasis, as it motivates sensation- and need-specific autonomic reflexes and adaptive behaviors (e.g., eating when hungry, terminating eating upon fullness, drinking when thirsty). Not all individuals have accurate interoceptive abilities. Individuals with eating disorders often have low perception of gastrointestinal, pain, and emotion sensations. Interoceptive dysfunct... Read More
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
07/29/2024
Locations: Louisville Center For Eating Disorders, Louisville, Kentucky
Conditions: Eating Disorder Symptoms
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: University of Louisville Research Foundation, Louisville, Kentucky
Conditions: Ulcerative Colitis
Register for Updates
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
NCT05915078
Recruiting
This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure (tympanostomy) using the Tula® System. The Registry will include up to 20 centers in the US and up to 200 patients for the initial evaluation. The FDA-approved Tula System includes the Tula Iontophoresis System (IPS) with TYMBION™ otic anesthetic for local anesthesia of the ea... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
07/19/2024
Locations: Advanced ENT and Allergy, Louisville, Kentucky
Conditions: Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Register for Updates
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: SystImmune Recruiting Site, Louisville, Kentucky
Conditions: Non Small Cell Lung Cancer, NSCLC, Lung Cancer, Breast Cancer, Esophageal Cancer, SCLC, Small Cell Lung Cancer, NPC, Nasopharyngeal Cancer
Register for Updates
Carnosine for Peripheral Arterial Disease Patients
NCT05371145
Recruiting
Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
Gender:
MALE
Ages:
Between 50 years and 80 years
Trial Updated:
07/18/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Peripheral Arterial Disease
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
NCT06005298
Recruiting
This randomized control trial study among Pre-exposure prophylactic users (PrEP) aims to learn and determine the efficacy of Screening, brief intervention, and referral to treatment (SBRIT) in reducing the risk of alcohol use. The main questions it aims to answer are: 1. How alcohol use impacts the PrEP continuum and to understand how early intervention and treatment approach affects alcohol use and PrEP adherence. 2. Investigate the effectiveness of the SBIRT intervention in preventing hazardo... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/17/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
Register for Updates
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
NCT04254185
Recruiting
This research is studying two surgical procedures in a large group of people to learn about how well these procedures work as a treatment for ulnar neuropathy at the elbow (UNE). Researchers want to see which surgery is more helpful for people with ulnar neuropathy. This research will determine if one surgery is better than the other to alleviate symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Neuropathy Ulnar
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Jewish Hospital, Louisville, Kentucky +4 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
NCT04830124
Recruiting
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Norton Cancer Center, Louisville, Kentucky
Conditions: Cutaneous Melanoma, Mucosal Melanoma
Register for Updates